Ascentage Pharma announced that it has received a $75 million equity investment from Takeda.
Ascentage Pharma (6855.HK), a biopharmaceutical company dedicated to developing innovative drugs in therapeutic areas such as oncology, hepatitis B, and aging-related diseases, announced that the transaction regarding Takeda's equity investment has been completed on June 20, 2024, and the payment has been received. According to the terms of the relevant agreement, Ascentage Pharma has successfully issued a total of 24,307,322 subscription shares to Takeda at a purchase price of HKD 24.09850 per share (approximately equivalent to USD 3.08549).
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
